Title:
ANTI-PD-L1/ANTI-CD47 BISPECIFIC ANTIBODY WITH STRUCTURE LIKE NATURAL ANTIBODY AND IN FORM OF HETERODIMER AND PREPARATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/109876
Kind Code:
A1
Abstract:
Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody includes amino acid substitutions at positions 366 and 399, and the other includes amino acid substitutions at positions 351, 407 and 409.
Inventors:
LIU JIAWANG (CN)
YANG YAPING (CN)
SONG NANMENG (CN)
KIM MAENGSUP (CN)
YANG YAPING (CN)
SONG NANMENG (CN)
KIM MAENGSUP (CN)
Application Number:
PCT/CN2018/118800
Publication Date:
June 13, 2019
Filing Date:
December 01, 2018
Export Citation:
Assignee:
BEIJING HANMI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/46; A61K39/395; A61P35/00; C12N15/13; C12N15/63; C12P21/08
Domestic Patent References:
| WO2017167919A1 | 2017-10-05 | |||
| WO2016109415A1 | 2016-07-07 | |||
| WO2016109415A1 | 2016-07-07 |
Foreign References:
| CN103429620A | 2013-12-04 | |||
| CN106883297A | 2017-06-23 |
Other References:
AUTOIMMUN REV, vol. 12, no. 11, 2013, pages 1091 - 1100
FRONT IMMUNOL, vol. 4, 2013, pages 481
NAT REV CANCER, vol. 12, no. 4, 2012, pages 252 - 264
TRENDS MOL MED., vol. 21, no. 1, January 2015 (2015-01-01), pages 24 - 33
CLIN CANCER RES., vol. 18, no. 24, 15 December 2012 (2012-12-15), pages 6580 - 7
ANTICANCER AGENTS MED CHEM., vol. 15, no. 3, 2015, pages 307 - 13
HEMATOL ONCOL STEM CELL THER., vol. 7, no. 1, March 2014 (2014-03-01), pages 1 - 17
IMMUNITY, vol. 39, no. 1, 25 July 2013 (2013-07-25), pages 61 - 73
J CLIN ONCOL., vol. 33, no. 17, 10 June 2015 (2015-06-10), pages 1974 - 82
EXPERT OPIN THER TARGETS, vol. 18, no. 12, December 2014 (2014-12-01), pages 1407 - 20
ONCOLOGY (WILLISTON PARK, vol. 28, no. 3, November 2014 (2014-11-01), pages 15 - 28
PROC NATL ACAD SCI USA, vol. 109, no. 17, 2012, pages 6662 - 6667
CURR OPIN IMMUNOL, vol. 21, no. 1, 2009, pages 47 - 52
FRONT IMMUNOL, vol. 4, 2013, pages 481
NAT REV CANCER, vol. 12, no. 4, 2012, pages 252 - 264
TRENDS MOL MED., vol. 21, no. 1, January 2015 (2015-01-01), pages 24 - 33
CLIN CANCER RES., vol. 18, no. 24, 15 December 2012 (2012-12-15), pages 6580 - 7
ANTICANCER AGENTS MED CHEM., vol. 15, no. 3, 2015, pages 307 - 13
HEMATOL ONCOL STEM CELL THER., vol. 7, no. 1, March 2014 (2014-03-01), pages 1 - 17
IMMUNITY, vol. 39, no. 1, 25 July 2013 (2013-07-25), pages 61 - 73
J CLIN ONCOL., vol. 33, no. 17, 10 June 2015 (2015-06-10), pages 1974 - 82
EXPERT OPIN THER TARGETS, vol. 18, no. 12, December 2014 (2014-12-01), pages 1407 - 20
ONCOLOGY (WILLISTON PARK, vol. 28, no. 3, November 2014 (2014-11-01), pages 15 - 28
PROC NATL ACAD SCI USA, vol. 109, no. 17, 2012, pages 6662 - 6667
CURR OPIN IMMUNOL, vol. 21, no. 1, 2009, pages 47 - 52
Attorney, Agent or Firm:
BEIJING INTELLEGAL INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF: